(Q46091585)

19 December 2017

title

Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms (English)

1 reference

19 December 2017

1 reference

1 reference

5

1 reference

19 December 2017

author name string

L A Wenning

1

1 reference

19 December 2017

A S Petry

2

1 reference

19 December 2017

J T Kost

3

1 reference

19 December 2017

B Jin

4

1 reference

19 December 2017

I DeLepeleire

6

1 reference

19 December 2017

E J Carlini

7

1 reference

19 December 2017

S Young

8

1 reference

19 December 2017

T Rushmore

9

1 reference

19 December 2017

F Wagner

10

1 reference

19 December 2017

N M Lunde

11

1 reference

19 December 2017

F Bieberdorf

12

1 reference

19 December 2017

H Greenberg

13

1 reference

19 December 2017

J A Stone

14

1 reference

19 December 2017

J A Wagner

15

1 reference

19 December 2017

M Iwamoto

16

1 reference

19 December 2017

language of work or name

English

0 references

publication date

11 March 2009

1 reference

19 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

19 December 2017

volume

85

1 reference

19 December 2017

issue

6

1 reference

19 December 2017

page(s)

623-627

1 reference

19 December 2017

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.12

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.12

Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.12

A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.12

The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.12

Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.12

UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.12

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.12

Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.12

Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.12

UDP-glucuronosyltransferases and clinical drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.12

Ways to fit a PK model with some data below the quantification limit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.12

HIV integrase structure and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.12

7 January 2021

Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.12

7 January 2021

The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.12

7 January 2021

Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid–liquid extraction and HPLC-MS/MS

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.12

7 January 2021

Identifiers

DOI

10.1038/CLPT.2009.12

1 reference

19 December 2017

1 reference

19 December 2017